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Abstract
Objective—High restenosis rates are a limitation of peripheral vascular interventions. Previous
studies have shown that surgical implantation of a tissue-engineered endothelium onto the
adventitia surface of injured vessels regulates vascular repair. In the present study, we developed a
particulate formulation of tissue-engineered endothelium and a method to deliver the formulation
perivascular to injured blood vessels using a percutaneous, minimally invasive technique.
Methods—Stainless steel stents were implanted in 18 balloon-injured femoral arteries of nine
domestic swine, followed by ultrasound-guided percutaneous perivascular injection of gelatin
particles containing cultured allogeneic porcine aortic endothelial cells (PAE). Controls received
injections of empty particles (matrix) or no perivascular injection (sham) after stent deployment.
Animals were sacrificed after 90 days.
Results—Angiographic analysis revealed a significantly greater lumen diameter in the stented
segments of arteries treated with PAE/matrix (4.72 ± 0.12 mm) compared with matrix (4.01 ± 0.20
mm) or sham (4.03 ± 0.16 mm) controls (P< .05). Similarly, histologic analysis revealed that PAE/
matrix-treated arteries had the greatest lumen area(20.4 ± 0.7 mm2; P< .05) compared with
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controls (16.1 ± 0.9 mm2 and 17.1 ±1.0 mm2 for sham and matrix controls, respectively) and the
smallest intimal area (3.3 ± 0.4 mm2; P < .05) compared with controls (6.2 ±0.5 mm2 and 4.4 ±0.5
mm2 for sham and matrix controls, respectively). Overall, PAE-treated arteries had a 33% to 50%
decrease in percent occlusion (P < .05) compared with controls. Histopathological analysis
revealed fewer leukocytes present in the intima in the PAE/matrix group compared with control
groups, suggesting that the biological effects were in part due to inhibition of the inflammatory
phase of the vascular response to injury.
Conclusions—Minimally invasive, perivascular delivery of PAE/matrix to stented arteries was
performed safely using ultrasound-guided percutaneous injections and significantly decreased
stenosis. Application at the time of or subsequent to peripheral interventions may decrease clinical
restenosis rates.
The most significant limitation of percutaneous revascularization of peripheral vessels due
to atherosclerosis is the high rates of restenosis. Despite initial technical success, restenosis
after angioplasty or stent implantation occurs in approximately 50% of the treated vessels,
such as the superficial femoral artery (SFA), within 6 to 12 months.1-3 Indeed, 1-year
patency rates in the SFA range between 22% and 61% after bare metal stent implantation.
While the use of drug-eluting stents in the coronary circulation has decreased restenosis
rates, a benefit of stenting and drug elution in peripheral arteries has yet to be clearly
demonstrated.4,5 A study of sirolimus-coated stents in the SFA reported that the drug-eluting
stents were not superior to bare metal stents.6 Studies have demonstrated a benefit of
paclitaxel-coated angioplasty balloons in the femoropopliteal artery7,8 and of paclitaxel-
coated stents in the SFA; however, long-term data in large, randomized clinical trials of
peripheral arterial disease are lacking.
Vascular restenosis is a complex response to injury that occurs after all arterial
interventions. The combined effects of local injury, thrombosis, inflammation and leukocyte
infiltration, spasm, smooth muscle cell (SMC) proliferation, and vessel remodeling induce a
hyperplastic response that encroaches on the blood vessel lumen.9,10 In recent years, the
adventitia has emerged as a key component of the vascular response to injury.11 Endothelial
cells (ECs), the major regulatory cells of the blood vessel, reside not only at the lumen
interface but also within the adventitia and throughout the vessel as vasa vasorum.
Experimental evidence suggests an association between vasa vasorum and neointimal
formation after injury.12 Therefore, it was postulated that supplementing the adventitial
endothelium may provide control over the response to vascular injury. Indeed, open surgical
placement of perivascular tissue-engineered ECs has been shown to inhibit intimal
thickening, stenosis, and negative remodeling in experimental models of vascular
injury.13-16 While open field surgery is amenable to direct adventitial placement, the
question arises as to whether tissue-engineered ECs could be applied by a minimally
invasive technique and retain efficacy. Development of techniques to deliver viable,
functional cells is essential to capitalize on the potential therapeutic impact and clinical
utility of cell transplantation.17 In the present study, we investigated the vascular response to
stent-induced injury in porcine femoral arteries treated with gelatin particles containing
allogeneic porcine aortic endothelial cells (PAE) injected adjacent to the affected vessel,
using an ultrasound-guided visualization technique.
Methods
Endothelial cell culture on Gelfoam particles
PAE were isolated from the aorta of healthy pigs by collagenase digestion and cultured on
gelatin particles (Gelfoam Powder; Pfizer, New York, NY) as previously described.18,19
Growth on Gelfoam was evaluated by periodic evaluation of cell number after enzymatic
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digestion.16 Cell viability was assessed by trypan blue exclusion, and EC was allowed to
reach a growth plateau prior to implantation. EC integrity was assessed by
immunocytochemistry using a mouse antiporcine CD31 antibody (MCA1746G; AB-D
Serotec, Raleigh, NC) to stain for platelet endothelial cell adhesion molecule (PECAM).
Nonspecific binding sites were blocked with normal donkey serum. Alexa Fluor 488-
conjugated donkey antimouse secondary antibody (1:300; Invitrogen, Grand Island, NY)
was added, and cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI).
Control particles (matrix) were incubated for up to 2 weeks in medium prior to implantation.
Biochemical and in vitro functional activity
Functional testing was performed on conditioned media from in vitro cohorts as previously
described.13,19 The production of heparan sulfate (HS), transforming growth factor-β1
(TGF-β1), nitric oxide (NO), and tissue inhibitor of metalloproteinase-2 (TIMP-2) were used
as markers of EC function. HS levels in conditioned media were determined using a
dimethyl methylene blue binding assay. TGF-β1, TIMP-2, and NO concentrations were
determined by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minn).
The ability of PAE on gelatin particles (PAE/matrix) to inhibit proliferation was determined
using conditioned media in an SMC growth stimulation assay. Porcine aortic SMC were
seeded in SMC growth medium (SmGM-2, Lonza BioScience [Walkersville, Md], contains
5% fetal bovine serum [FBS], fibroblast growth factor, and epidermal growth factor),
allowed to attach for 24 hours, and growth arrested for 48 to 72 hours. Conditioned and
control media was diluted 1:1 with 2 × SmGM-2 and added to the wells. Cell number was
determined after 3 days by colorimetric analysis (CellTiter 96 Proliferation Assay; Promega,
Madison, Wisc). Growth factor stimulation (GFS) was determined by dividing the
absorbance (ABS) of conditioned or control media wells by the ABS for 5% FBS wells. The
effect of conditioned media on SMC growth factor stimulation was then determined by the
following equation:
The ability of PAE/matrix-conditioned media to suppress markers of inflammation and
thrombosis was determined using real-time polymerase chain reaction (RT-PCR). Briefly,
human aortic EC (HAE) were grown to confluence and serum-starved in 0.5% FBS for 24
hours. Cells were treated with endothelial basal medium supplemented with 0.5% FBS
(control media) alone or supplemented with 1 μg/mL of platelet factor-4 (PF-4; Peprotech,
Rocky Hill, NJ) or with media conditioned by PAE/matrix supplemented with 1 μg/mL of
PF-4 for 3.5 hours. PF-4 is a proatherogenic platelet molecule that has been shown to
increase E-selectin RNA as well as other inflammatory and thrombotic markers and was
added to EC cultures to simulate an injured state.20 RNA samples were harvested from each
individual well using the RNeasy Mini spin column kit (Qiagen, Valencia, Calif) according
to the manufacturer's protocol. The concentration of the representative RNA samples was
determined using the Experion capillary electrophoresis apparatus with the Experion RNA
StdSens analysis kit (Bio-Rad, Hercules, Calif). The resulting total RNA samples from each
treatment group were used for RT-PCR analysis to determine the expression levels of
various inflammatory and thrombotic genes (Table I). The “2−ΔΔCt” calculation for relative
gene expression comparison method was used for PCR data analysis: the relative expression
level of each gene (Ctgene) was first normalized to the house-keeping marker hypoxanthine
ribosyltransferase (HPRT) to generate the ΔCt value (Ctgene − CtHPRT), which was then
further normalized to the respective treatment control (control media with PF-4) to generate
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the δδCt. The 2−ΔΔCt value of each gene representing the relative expression level was
calculated and plotted for data presentation.
In vivo biologic activity of transplanted endothelial cells
The ability of the PAE/matrix to control vascular repair when injected adjacent to stented
porcine femoral arteries was assessed. This study conformed to the guidelines specified in
the National Institutes of Health “Guide for Care and Use of Laboratory Animals” and was
approved by the Institutional Animal Care and Use Committee of Concord BioMedical
Sciences and Emerging Technologies (Lexington, Mass). Male domesticpigs,43.1 kg ± 0.9
kg at implant, were obtained from Animal Biotech, Inc (Danboro, Pa). Anesthesia was
induced and animals monitored throughout the procedure as previously described.18 To
prevent or reduce the occurrence of thrombotic events, animals were treated on day 1 with
aspirin (650 mg per os [PO]) and clopidogrel (300 mg, PO). The animals were then treated
with aspirin (81 mg, PO) and clopidogrel (75 mg, PO) daily thereafter.
A total of nine pigs were implanted with stents in the right and left femoral arteries (total
stented arteries, 18). This study was conducted in compliance with the Food and Drug
Administration Good Laboratory Practice Regulations. Briefly, right carotid arterial access
was obtained, and a 5.0-mm-diameter angioplasty balloon (Abbott Vascular, Redwood City,
Calif) was advanced to the left and right femoral arteries under fluoroscopic guidance (GE
9800 C-arm fluoroscope [GE Healthcare, Wauwatoga, Wisc], resolution 15 frames per
second). The right and left arteries were injured by 30-second balloon inflations at 10
atmospheres pressure (three inflations per side, in overlapping segments) to ensure adequate
removal/injury of endogenous luminal endothelium. Biliary stents (5.5 mm × 18 mm,
Herculink; Abbot Vascular) were introduced into the left and right femoral arteries.
Angiography was performed, and the stents were expanded with the 5.0-mm-diameter
angioplasty balloon at 10 to 12 atmospheres pressure. Heparin (50-200 U/kg intravenously)
was administered to prolong activated clotting time (ACT) to a target range of ≈ 275
seconds during stent deployment. After final angiography to assess vessel patency, the
femoral arteries were treated with minimally invasive injections of ≈ 70 mg/3.0 mL media
of control matrix (n = 6 arteries, two arteries per animal), PAE/matrix (n = 6 arteries, two
arteries per animal), or no perivascular injection (sham, n = 6 arteries, two arteries per
animal) adjacent to the perivascular tissue of the stented artery. Contralateral arteries
received the same treatment to allow for blood collection at 4,8, and 12 weeks to assess
differences in clinical pathology, hematological, serum chemistry, and coagulation
parameters between treatment groups. Animals were euthanized at 90 days, and the femoral
arteries plus stent were processed for histologic evaluation. For each artery, angiography
was performed prior to injury, immediately after stent deployment, and on day 90.
Quantitative angiography was performed on recorded images using Centricity Cardiology
CA1000 Cardiac Review 1.0 (SpaII) QCA software in a blinded fashion (GE Healthcare).
Measurements were also made of the reference unstented vessel and minimum lumen
diameter (MLD) at 90 days.
To verify the location of the injected material, a separate non-Good Laboratory Practice
study was performed in seven pigs. Stented and nonstented arteries were injected with either
control particles stained with methyl blue or particles seeded with PAE. All pigs were
sacrificed within 1 day, and tissue was isolated to determine the location of the injected
material.
Ultrasound-guided percutaneous injections
Control matrix or PAE/matrix was delivered to the perivascular site of stented femoral
arteries percutaneously using a syringe and hypodermic needle. Delivery of the material was
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visualized by ultrasound-guided needle placement techniques using echogenic needles (18G
Chiba biopsy needle; Cook Medical, Bloomington, Ind). Aportable ultrasound system
(model t-3000; Terason, Inc, Burlington, Mass) was used to visualize the targeted
perivascular tissue, the needle position and movement, and to guide the placement of the
material. Proximal and distal ends ofthe stent (visible under ultrasound) were used as
landmarks to ensure that the injection site with respect to stent placement was similar among
arteries. Injection target location was adjacent to the perivascular tissue.19 Delivery to the
sites was confirmed by continuous visualization of the injection site and blood flow during
and postinjection by color-Doppler and spectral-Doppler ultrasound scan.
Tissue processing
On the 90th postoperative day, animals were euthanized with intravenous potassium
chloride (40 mEq). The femoral arteries were perfused at 100 mm Hg with Ringer's lactate
solution, followed by 10% neutral formalin to fix the arteries in situ. The arteries were
isolated and the vessel divided into five 10-mm-long segments: far proximal to the stent (1-3
mm upstream from the stent), proximal stent, middle of the stent, distal stent, and far distal
to the stent (1-3 mm beyond the stent). The stented segments were methacrylate embedded
and non-stented vessel segments were paraffin embedded. Slides with 5-μm sections were
obtained and stained withMayer's hematoxylin and eosin and Verhoeff's van Gieson elastin
stains. Leukocytes were identified after antigen retrieval at 80°C in 1× Dako Target
Retrieval solution for 2.5 hours and overnight incubation at 4°C with mouse antiporcine
CD45, allotypic variant (clone: MAC323, AB-D Serotec; 1:10 dilution). The CSAII
detection system (K1497; Dako Inc, Carpinteria, Calif) was used to detect primary antibody-
tissue antigen binding. Porcine spleen was used as a positive control and antibody diluent
solution was used as a negative control. PAE were identified as described above combined
with avidin-biotin peroxidase complex or Alexa Fluor detection methods. All sections were
counterstained with Mayer's hematoxylin solution (Sigma Chemical Co, St. Louis, Mo).
Slides were read and interpreted by a board-certified veterinary pathologist blinded as to
treatment groups. Histomorphologic findings were graded on a scale from 0 through 3,
depending upon severity (0 = absent; 1 = present in tissue, but minimal feature; 2 = present
in tissue, notable feature; 3 = present in tissue, overwhelming feature).21
Histomorphometric analysis was performed on all segments. The intimal thickness and area
(I), lumen (L), media (M), and stent (S) areas were measured using a computerized digital
planimetry system comprised of an Olympus DP-70 digital, BX-41 microscope and
MicroSuite Biological (version 2.5) software. Measurements were made by a blinded
observer of the proximal, middle, and distal segments for each vessel and averaged so that
each vessel resulted in one data point. Comparisons were also made among groups for each
of the proximal, middle, and distal planes.
Statistical analysis
All data are presented as mean ± standard error (SE). Statistical analysis comparing stented
arteries of the different treatment groups used a one-way analysis of variance and a Tukey-
Kramer multiple comparison test with JMP version 7.0.1 software (SAS Institute, Cary,
NC). Differences were not considered significant unless the probability of the calculated
statistic was less than 0.05.
Results
Biochemical and in vitro functional activity of PAE/Gelfoam
PAE/matrix were assayed for cell number, viability, TGF-β1, HS, NO, and TIMP-2
production. PAE cultured on gelatin particles followed a growth pattern similar to that
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observed for cells cultured on gelatin sponges (Fig 1).16 The number of PAE recovered from
the matrix increased exponentially from 1.0 × 104 cells/mg on day 0 to 6.8 × 104 cells/mg
when they reached confluence (day 12–15). The viability of the recovered cells was
approximately 90%. Thereafter, the cell number was fairly constant up to 8 days
postconfluent (average of 6.1 × 104 cells/mg on culture day 22). Significant levels of HS
(0.632 ± 0.09 μg/mL/d), TIMP-2 (23.4 ±1.3 ng/mL/d), NO (1.1 ± 1.1 μmol/L/day), and
TGF-β1 (312 ± 12.5 pg/mL/d) were detected in conditioned media collected from
postconfluent in vitro cohorts. Moreover, PAE cultured on gelatin particles stained positive
for the endothelial marker PECAM (Fig 1).
The inhibitory potential of PAE/matrix was further investigated in growth, thrombotic, and
inflammatory assays. Conditioned medium inhibited growth factor stimulation of cultured
SMC proliferation by 36.3 ± 1.6% (P < .05) and suppressed the PF-4 induction of various
pro-thrombotic and proinflammatory gene expression in HAE. PAE/matrix-conditioned
media significantly suppressed the PF-4 induction of vascular cell adhesion molecule-1 by
69.7 ± 2.7% (P < .05), intercellular adhesion molecule-1 by 40.6 ± 12.9% (P < .05), tissue
factor (TF) by 45.1 ± 6.2% (P < .05), E-selection by 82.3 ± 2.9%(P< .05), and interleukin-8
by 71.6 ± 4.9% (P < .05; Fig 1).
In vivo efficacy of perivascular endothelial cells
The pigs used in this study were randomly selected to receive one of the following
treatments by ultrasoundguided percutaneous injection of gelatin particles into the
perivascular tissue of stented femoral arteries: PAE/matrix, control matrix, or nothing
(sham). All injections occurred without incident (Fig 2). Acute dissection to the femoral
arteries in seven pigs confirmed location of the material and PAE directly adjacent to the
adventitia of the artery and that a single injection of 70 mg/3 mL covered the length of the
stented segment (Fig 2). The remaining animals were euthanized at 90 days. All incisions
healed well, and all animals gained weight throughout the postoperative period. Mean
hematologic and clinical chemistry values from all groups were similar and within expected
ranges. All of the femoral arteries were patent at the 90-day time point. Angiographic
analysis performed at 90 days postinjury revealed less stenosis and significantly greater
MLD in the stented segments of arteries treated with PAE/matrix (Fig 3; Table II; P < .05).
There was no difference in MLD of sham arteries compared with arteries that received
control particles. Morphometic analysis revealed similar results (Fig 3; Table III). Treatment
with PAE/matrix reduced the intimal area from 6.20 ± 0.50 mm2 and 4.4 ± 0.50 mm2 for
sham and matrix controls, respectively, to 3.3 ± 0.40 mm2 (P < .05). PAE/matrix also
significantly increased the lumen area from 16.1 ± 0.90 mm2 and 17.1 ± 1.0mm2 for sham
and matrix controls, respectively, to 20.4 ± 0.70 mm2 (P < .05) and decreased the %
occlusion compared to sham and matrix controls by 50% and 33%, respectively (P < .05).
The average intimal area of arteries treated with control matrix was less than the sham
controls (P < .05; Table III). However, when individual planes (proximal, mid, distal; Fig 4)
were analyzed, only the PAE/matrix group had statistically significant less intimal area than
the sham control group. There was no difference in stent diameter observed among groups at
90 days. There were no adverse edge effects observed in the far-proximal or fardistal
sections of any of the animals.
Histopathological analysis (Table IV) revealed no adverse effects from perivascular
injection of gelatin particles on the perivascular tissue or tissue healing response within the
adjacent stented femoral arteries. Inflammation at the delivery site, intimal fibrin, adventitial
fibrosis, and SMC necrosis were all minimal and comparable between groups. Injury score
and adventitial vascularization were also assessed with no significant differences among
groups. Endothelialization was generally complete and comparable among treatment groups
(Fig 5). Neointimal hypocellularity, which generally increases in areas of mural injury with
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increased neointimal production, was significantly greater in the two control groups
compared with the PAE/matrix group (Fig 5). Fewer leukocytes (identified by CD45
staining; Fig 5) were present in the intima in the PAE/matrix group compared with the
matrix (average difference of one severity point) and sham (average difference of two
severity points) control groups. No positive staining for CD45 was observed in the media of
any animals. Minimal CD45 staining was present in the adventitia with no differences
observed between groups.
Discussion
Despite the improvements in endovascular techniques in the last 20 years, restenosis is still a
significant limitation of most arterial interventions performed in the peripheral circulation.8
In particular, interventional treatments in the SFA have long suffered from excessively high
restenosis rates regardless of treatment with balloon angioplasty and stenting.5,22 Several
studies have also reported stent fractures when used in the SFA that have been associated
with angiographic (>50%) stenosis. Currently, no large, randomized trials have shown
significant clinical benefit with the use of drug-eluting stents6 or other agents such as
glycoprotein IIb/IIIa platelet receptor-blocking agents23 for restenosis associated with
peripheral arterial interventions.
The endothelial technology presented here represents a novel approach to addressing the
complications associated with peripheral interventions. The use of ECs to modify
intravascular injury has been under active investigation for some time, primarily in the form
of methods to endothelialize stents and/or the damaged native vessel.24,25 However, the
ability of ECs to regulate neointimal formation may not be limited to a luminal location, and
studies have suggested that the adventitia and vasa vasorum influence the vessel response to
injury.11,12 Perivascular placement also presents a desirable location for logistical reasons –
the cells and their secreted factors are not diluted or rapidly cleared by convective flow, nor
do they impede flow. Indeed, implantation of perivascular, allogeneic tissue-engineered ECs
has been shown to regulate the response to vascular injury and decrease stenoses13-16,26 and
has been investigated in the clinical setting of arteriovenous access for hemodialysis.27
However, all of these studies utilized a porous, three-dimensional sponge as the support
matrix for implantation of quiescent and therapeutic ECs. The application of this technology
was therefore limited to those that require an open surgical procedure. An aim of the present
study was to determine if this technology could be adapted to an injectable formulation and
delivered utilizing a minimally invasive procedure, and if such a delivery would produce
efficacy in vivo. The necessity of culturing ECs on matrices prior to implantation rather than
direct injection of cell suspensions has been demonstrated previously.28-31 ECs are
anchorage-dependant and require attachment to a substrate for optimal viability and
function.16,28,32 Indeed, recent literature has highlighted the importance of developing
transplantable scaffolds that optimize cell attachment, viability, and function to the
widespread use and success of cell transplantation to treat or prevent organ and tissue
failure.17 It has also been shown that matrix-adhered ECs have significantly reduced
expression of constitutive and cytokine-upregulated costimulatory and adhesion molecules
compared with free ECs, and in particular, a marked abrogation of MHC II-regulated
immune reactivity, resulting in muted host immune reaction to both allogeneic or
xenogeneic matrix-adhered ECs.28 We therefore developed a matrix-embedded EC
formulation that was amenable to minimally invasive injection while maintaining a
regulatory phenotype that maximally controlled inflammation, intimal thickening, and mural
remodeling.
PAE were grown on gelatin particles and secreted similarlevels of HS, TGF-β1,FGF-2,NO,
and TIMP-2 to that from cells grown on the sponges, suggesting that both types of matrices
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supported the quiescent and therapeutic endothelial phenotype.33 This was confirmed in
vivo by the ability of PAE/matrix, injected percutaneously under ultrasound\guidance, to
inhibit intimal formation and stenosis in a porcine femoral stent model. A stent model was
used to assess the ability of the PAE/matrix to control the response to a chronic vascular
injury and to precisely locate the area of injury at a late time point. Because the PAE/matrix,
as well as the gelatin matrix alone, degrades in vivo within 6 to 8 weeks, a 90-day time point
was selected for this study to assess the durability of therapeutic effects.14,15 Stented arteries
in the PAE/matrix group had significantly greater MLD by angiography and significantly
greater lumen area and less intimal formation compared with sham controls by histology at
90 days. It is interesting to note that upon initial evaluation of histologic samples, the
injection of matrix alone, while not as great a difference as injection of matrix containing
PAE, appeared to have some beneficial effects on intimal area compared with the sham
control. However, upon further detailed analysis of histologic planes (Fig 4), there was no
significant therapeutic effect of the matrix group. This was also the case for the angiographic
analysis; control sham and matrix groups had almost identical MLD, while the PAE/matrix
groups have a significantly larger MLD. Furthermore, it also appears that only the PAE/
matrix group truly inhibited leukocyte infiltration into the intima. It is therefore more likely
that the therapeutic benefits are due to the presence of the matrix-embedded cells and not the
matrix alone.
Adverse events that have been associated with drugeluting stents include inflammation,
fibrin deposition, medial necrosis, intra-arterial hemorrhage, and incomplete healing or
endothelialization at the stent struts.34 All of these phenomena were evaluated in the present
study. All stented vessels were completely endothelialized by the 90-day time point. There
was no increase in inflammation, fibrin deposition, or medial necrosis due to the presence of
perivascular PAE/matrix. Indeed, analysis of CD45-stained tissue sections from PAE/matrix
animals revealed no leukocytes present in the intima of the arterial segments, compared with
a moderate degree of CD45+ cells in the control groups. This observation suggests that
perivascular ECs, or factors released by the cells, may provide control over intimal
formation by influencing the inflammatory phase of the vascular response to stent-induced
injury .9,10,35 This is similar to the proposed mechanism of mesenchymal stem cell (MSC)
transplantation, where MSCs have been shown to modulate T-cell-mediated immunologic
responses and inhibit dendritic cell maturation through paracrine interactions with MSC-
soluble factors.29,36 The in vivo data are further supported by the in vitro results.
Conditioned media collected from PAE grown on gelatin particles suppressed PF-4
induction of prothrombotic and proinflammatory genes in cultured HAE and inhibited
growth factor-stimulated SMC proliferation.
In addition, placement of the PAE/matrix in the adventitia and not associated with a stent
has the advantage of allowing for application in clinical settings where stent placement may
not be feasible, such as arteries located below the knee. A limitation of the present study was
that the animals were healthy, and therefore the impact of angioplasty and stenting of an
existing lesion was not assessed; however, the results suggest that percutaneous delivery of
tissue-engineered EC to the adventitia promotes vascular repair after stent-induced injury.
Injections of tissue-engineered ECs coincident with balloon angioplasty or stenting of
peripheral arteries may improve the longterm success rates of these procedures. A clinical
study assessing the safety and feasibility of ultrasound-guided percutaneous injections of
tissue-engineered endothelium (derived from allogeneic human aortic endothelial cells) in
patients undergoing stent placement in the SFA is currently ongoing.
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Clinical Relevance
Endovascular interventions performed in the peripheral circulation are limited by
restenosis. Thrombosis, inflammation, smooth muscle cell proliferation, and negative
remodeling result in significant obstruction to the blood vessel lumen. While some trials
have shown the beneficial effects of drug-eluting stents, data from large, randomized
controlled clinical trials of peripheral arterial disease are lacking. In a large animal model
of peripheral arterial stenting, we demonstrated that perivascular, ultrasound-guided
injections of matrix-embedded endothelial cells significantly increased lumen diameter
and decreased stenosis at 90 days. Development of techniques to deliver viable,
functional cells is essential to realize the potential therapeutic impact of cell
transplantation and expands the opportunity for the clinical application of cell-based
therapy subsequent to endovascular interventions for peripheral arterial disease.
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Fig 1.
Characterization of porcine aortic endothelial cells (PAE) on gelatin particles. A, PAE
cultured on particles followed a growth pattern similar to cells grown on sponges or standard
tissue culture plastic. B, The preservation of endothelial cell integrity was determined by
platelet endothelial cell adhesion molecule (PECAM) staining. Green cells indicate positive
PECAM staining; blue indicates nuclei. C, Suppression of platelet factor-4 (PF-4) induced
inflammatory and thrombotic gene expression on human aortic endothelial cells (HAE) by
PAE/matrix-conditioned media. ICAM-1, Intercellular adhesion molecule-1; IL-8,
interleukin-8; TF, tissue factor; VCAM-1, vascular cell adhesion molecule-1. *P < .05
compared with PF-4 and control media.
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Fig 2.
Images depict ultrasound-guided percutaneous delivery of porcine aortic endothelial cells
(PAE)/matrix adjacent to perivascular tissue of femoral arteries (A) at the time of injection
and (B) postinjection. C and D, Delivery site adjacent to the femoral artery was confirmed
after femoral cutdown. Stent struts are visible within the artery, which is encapsulated with
injected methyl blue-stained gelatin particles. E, Histologic section of unstented femoral
artery stained with Mayer's hematoxylin solution confirms delivery of particles adjacent to
perivascular tissue. F and G, Sections of unstented femoral arteries stained with CD31
identifies retention of PAE within the particles after percutaneous injection adjacent to the
perivascular tissue.
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Fig 3.
Representative day-90 angiograms (A) and photomicrographs of Verhoeff's elastin-stained
arterial cross-sections (B). Comparison of the angiograms shows an increase in stenosis in
the stented region of control arteries (left and middle panels, black arrows) compared with
arteries treated with porcine aortic endothelial cells (PAE)/matrix (right panel). Histologic
sections show significantly greater intimal area in control sham (left panel) and matrix
(middle panel) arteries compared with arteries treated with perivascular PAE/matrix. I,
Intima; L, lumen; M, media.
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Fig 4.
Bar graphs of tissue plane analysis. (A) Lumen area, *P< .05 compared with sham
andmatrix control groups; (B) intimal area; (C) % occlusion; and (D) intimal thickness, §P
< .05 compared with sham control group. There was no statistical difference between the
sham and matrix control groups when comparing the proximal, mid, or distal planes. PAE,
Porcine aortic endothelial cells.
Nugent et al. Page 16
J Vasc Surg. Author manuscript; available in PMC 2013 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig 5.
Representative photomicrographs of hematoxylin and eosin-stained arterial cross-sections
depict (A) stent endothelialization (arrows), (B) reduced hypocellularity in porcine aortic
endothelial cells (PAE)/matrix group (dashed circle) compared with (C) control matrix
group (dashed brackets), (D) minimal inflammation associated with stent struts (arrow) in
PAE/matrix group. E, Representative photomicrographs of CD45-stained arterial cross-
sections depict no positive staining in the intima of PAE/matrix arteries (top panel) and
moderate positive staining in the control matrix (middle panel) and sham (bottom panel)
groups. Arrows point to positive CD45 staining. F, Bar graph demonstrates fewer CD45-
positive leukocytes (severity score = 0 ± 0) present in the intima of day 90 PAE/matrix
animals compared with control matrix (severity score = 1 ± 0) and sham (severity score = 2
± 0.8) groups.
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Table I
Primer sets for real-time polymerase chain reaction
Genes Functional pathways Primers sequences (5′–3′)
Vascular adhesion molecule-1 Inflammation CTGTTGAGATCTCCCCTGGA
CGCTCAGAGGGCTGTCTATC
Intercellular adhesion molecule-1 Inflammation TCAAGGGTTGGGGTCAGTAG
GAAGTGGCCCTCCATAGACA
Tissue factor Coagulation ACCTCGGACAGCCAACAATTCAGA
Thrombosis ATCCCGGAGGCTTAGGAAAGTGTT
E-selectin Inflammation AGGTTCCTTCCT GCCAAGTGGTAA
ATTGAGCGTCCATCCTTCAGG ACA
Interleukin-8 Inflammation AGAAACCACCGGAAGGAACCATCT
Smooth muscle cell activation AGAGCTGCAGAAATCAGGAAGGCT
Hypoxanthine ribosyltransferase Metabolism AGATGGTCAAGGTCGCAAGC
House-keeping GGACTCCAGATGTTTCCAAACTCAAC
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Table III
Histopathological characteristics of stented porcine femoral arteries
Characteristics Sham Matrix PAE/matrix
Number of arteries, n 6 5a 6
Intima area (mm2) 6.2 ± 0.5 4.4 ± 0.5b 3.3 ± 0.4b
Neointimal thickness (mm) 0.40 ± 0.03 0.29 ± 0.04 0.20 ± 0.02b
Lumen area (mm2) 16.1 ± 0.9 17.1 ± 1.0 20.43 ± 0.70b
Lumen/artery ratio 0.65 ± 0.02 0.72 ± 0.03 0.77 ± 0.02b
Stent diameter (mm)c 5.5 ± 0.13 5.4 ± 0.07 5.6 ± 0.04
% Occlusiond 28 ± 2.1 21 ± 2.8 14 ± 1.8b
PAE, Porcine aortic endothelial cells.
a
Right femoral artery of one control matrix animal removed from data analysis due to excessive procedural injury and subsequent intimal
formation (complete occlusion).
bP < .05 compared with sham.
cStent diameter (Sd) = 2 × √(Sa/π).
d% Occlusion = (I/I + L) × 100.
J Vasc Surg. Author manuscript; available in PMC 2013 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Nugent et al. Page 21
Table IV
Semiquantitative histomorphology19
Characteristic Sham Matrix PAE/matrix
Intimal fibrin 0.06 ± 0.04 0.0 ± 0.0 0.0 ± 0.0
Endothelializationa 4.0 ± 0.0 4.0 ± 0.0 4.0 ± 0.0
Adventitial fibrosis 1.0 ± 0.32 0.33 ± 0.27 0.72 ± 0.16
Neointimal hypocellularityb 1.33 ± 0.12 1.1 ± 0.22 0.44 ± 0.14c
Medial smooth muscle cell necrosis 0.28 ± 0.13 0.0 ± 0.0 0.06 ± 0.06
Adventitial vascularization 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Inflammationd 0.61 ± 0.04 0.53 ± 0.09 0.60 ± 0.16
Injury scoree 0.04 ± 0.04 0.0 ± 0.0 0.1 ± 0.04
PAE, Porcine aortic endothelial cells.
a
Endothelialization was scored on a scale from 0 to 4 (0 = absent; 1 < 25%; 2 = 25-75%; 3> 75%; 4 = 100%) and depended upon the extent of the
circumference of the artery lumen showing coverage with endothelial cells.
bCharacterized by areas of neointima with increased interstitial matrix within/around smooth muscle cells.
cP < .05 compared with control arteries.
dSum of strut inflammation scores/No. of stent struts.
e
The injury score depended on the part of the arterial wall perturbed by the stent. Injury was scored from 0 to 3 on a per-strut basis and the average
was calculated per plane (0 = IEL intact; 1 = IEL disrupted; 2 = tunica media disrupted; 3 = tunica adventitia disrupted).
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